A specific ELISA for measuring neurofilament heavy chain phosphoforms by Petzold, A et al.
A specific ELISA for measuring neurofilament
heavy chain phosphoforms
A. Petzold ∗ G. Keir A.J.E. Green G. Giovannoni
E.J. Thompson
Department of Neuroimmunology, Institute of Neurology, University College
London, Queen Square, London WC1N 3BG, United Kingdom
Abstract
Neurofilaments (Nf) are the major constitute of the axoskeleton and Nf body
fluid levels are an important tool for estimating axonal degeneration in vivo. A
new sandwich ELISA which allows to quantify the NfHSMI35 phosphoform from
the CSF, brain tissue and cell–culture homogenate is presented. The sensitivity of
the NfHSMI35 ELISA calculates to 0.2 ng/mL with a recovery of 119% and a mean
within- and between–batch precision of 10.6%, 23%, respectively. CSF NfHSMI35 was
stable at 4◦C, not influenced by freeze–thaw cycles and proteolysis present at room
temperature could be prevented by adding protease inhibitors. Aggregate formation
was observed for HPLC purified bovine NfH and could be resolved by sonication.
CSF NfH was found to be significantly more resistant to protease digestion by
alkaline phosphatase than NfL.
The upper reference value for CSF NfHSMI35 levels (0.73 ng/mL) was defined
as the 95% cumulative frequency from 416 CSF samples. Based on this cut–off a
significantly higher proportion of patients with amyotrophic lateral sclerosis, space–
occupying lesions, disc–prolapse and subarachnoid haemorrhage had pathological
elevated NfHSMI35 levels if compared to patients with cluster headache or demyeli-
nating disease.
In order to facilitate for future work the comparison between ELISA, immunoblot-
ting and immunocytochemistry, properties of the monoclonal capture antibodies
have been reviewed and a new nomenclature is proposed.
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Neurofilaments (Nf) are the principal component of the axoskeleton and re-
leased during axonal damage. Body fluid levels of Nf are an important can-
didate to be validated as a surrogate marker for axonal degeneration in neu-
rological disorders. At present there are no commercial ELISA kits available
for the quantification of any of the three Nf subunits. One group developed
a sandwich ELISA technique for the detection of the Nf light chain (NfL)
in the cerebrospinal fluid (CSF), based on in–house antibodies [1]. Confirma-
tion of the results derived by this group is however hampered by the non–
availability of the antibodies. Another group published an ELISA for NfL and
two phosphoforms of the Nf heavy chain (NfH) in brain homogenate [2], but
the reproducibility of this assay was not rigorous.
Nf are obligate heteropolymers composed of 3 subunits (NfL, NfM, NfH) and
belong to the class IV–intermediate filaments [3]. Nf subunits share a α–helical
rod domain which is required for the formation of oligomers. It has been sug-
gested that the N–terminal head domain has regulatory functions of Nf as-
sembly and that the C–terminal tail domain which is the major site of phos-
phorylation, plays a role in protein–protein and protein organelles interaction
[4]. The length of the C–terminal tail domain differs considerably between
the Nf subunits and accounts for the different molecular mass. The molecular
mass of NfL is 68 kDa and of NfM 160 kDa in SDS gels [3]. NfH is coded on
chromosome 22q12.2 and consists of 1020 amino acids [5], with a molecular
mass of 111 kDa. Dependent on the degree of phosphorylation migration in
sodium dodecyl sulfate (SDS) gels slows down, thus explaining the range of
190 to 210 kDa reported in the literature. The phosphorylated NfH has shown
to be relatively resistant to protease activity [6], whilst NfL is not [7,8].
The aim of this study was to develop a sandwich ELISA method for the
quantification of phosphorylated NfH in the CSF of neurological patients.
1 Materials and methods
1.1 Antibodies
Capture (first) antibodies: mouse monoclonal anti–NfH antibodies (SMI clones
32, 33, 34, 35, 37, 38, 310, 311) were purchased from Sternberger Monoclonals
(Sternberger Monoclonals Incorporated, Utherville, USA) and Sigma (clone
NE14, Sigma, UK). Mouse monoclonal anti–NfL was purchased from Sigma
(clone NR4). The details of the capture antibodies are summarised in Table 1.
The detector (second) antibody: rabbit polyclonal anti–NfH and anti-NfL was
purchased from Affinity (Affiniti Research Products, Exeter, UK). The indi-
cator (third) horse–radish peroxidase (HRP) labelled swine polyclonal anti–
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rabbit antibody was purchased from DAKO (DAKO, Copenhagen, Denmark).
1.2 Chemicals
Sodium barbitone, barbitone, ethylene diamine tetra acetic disodium salt
(EDTA), type III bacterial alkaline phosphatase (ALP, P4252), protease in-
hibitor cocktail (PI, P8340), calcium lactate, 30% hydrogen peroxide, NaHCO3,
Na2CO3, Tween 20, bovine serum albumin (BSA) were of analytical grade
(Sigma). TMB was purchased from DAKO. Hydrochloric acid (HCl) was ob-
tained from Merck (Darmstadt, Germany). Bovine HPLC purified GFAP and
NfM were obtained from Affiniti Research Products. NUNC Maxisorb Mi-
crotitre plates were obtained from Life Technologies (Paisley, Scotland).
1.3 Standards
Bovine NfH and NfL were obtained from Affiniti Research Products. Bovine
Nf subunits were chosen instead of Nf of human origin as the supply of pro-
teins from human brains could not be guaranteed. A potential way around
this, that may be explored in future work, would be the use of recombinant
protein technology, however this approach has the disadvantage that post–
transcriptional modifications such as phosphorylation and glycosylation are
absent. The standard curve based used for the NfH assay was calculated from
dilutions of 50 µg HPLC purified bovine NfH protein in barbitone buffer (pH
8.9) containing 0.1% bovine serum albumin, 6 mM EDTA and ranged from 0
to 2 ng/mL. The standards for the NfL assay were made from 50 µg HPLC
purified bovine NfL protein similar to the procedure described for NfH and
ranged from 0 to 0.5 ng/mL. The standards were in 1 mL aliquots at -20◦C.
1.4 CSF samples
In total CSF samples from 638 neurological patients undergoing a routine
diagnostic lumbar puncture were obtained. The selection was coded and ran-
domised from the department’s sample library. The CSF samples were cen-
trifuged on receipt and stored at 4◦C. Analysis was performed within 1 week.
Pooled CSF was obtained by taking an aliquot from routine samples. Ten pools
of 10 mL were obtained and stored at -70◦C until further analysis. The CSF
analysis was in accordance with the MRC guidelines for handling of biological
specims and approved by the local ethics committee.
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1.5 Preparation of cell culture homogenate
Primary cortical astrocytic, microglial and neuronal cell cultures were cul-
tured and prepared from Wistar rats (1–2 days old, 7 days old and day 17 of
gestation, respectively) as described [9,10,11]. Astrocytes were cultured for 13
days, removed from the flask by trypsin digestion and seeded onto tissue cul-
ture plates at a density of 106 cells/well (1500 cells/mm2) [9,10]. Neurons were
dissociated as above and seeded onto poly–ornithine–coated cell culture plates
at a density of 2.5 ×106 cells/well (3750 cells/mm2) [9]. Microglia cells were
plated at 6 ×104 per 13-mm coverslip [11]. Culture medium was decanted,
cells were washed with sample buffer, scratched off the plate/coverslip and
snap frozen in 1 mL of sample buffer. Cells were sonicated for 1 minute on ice
with a cover of argon gas, spun down at 20,000 g. The supernatant was stored
at -70◦C until further analysis.
1.6 Preparation of brain and spinal cord homogenate
Snap-frozen blocks of brain and spinal cord tissue from of between 0.5 and 1g
wet weight, were cut and re-suspended at 1:5 g/mL in Tris-HCl buffer (100mM
Tris, pH 8.1 with 1% Triton X-100). Samples were homogenised on ice by
sonication, triturated 3 times through 19 and 21 gauge needles and spun at
20,000g. Myelin protein was extracted by adding di–iso–propyl ether (1:5,000),
centrifugation at 20,000 g and removal of the lipid layer. The protease inhibitor
cocktail was added in a dilution 1:100 to supernatant. After dilution into
aliquots of 1:1,1000, 1:5,000, 1:10,000 and 1:100,000 the samples were stored
at -70 ◦C until further analysis.
1.7 Analytical procedure
The microtitre plates were coated overnight with capturing antibody diluted
1:5000 in 0.05 M carbonate buffer, 100 µL, pH 9.5. The plate was washed
with barbitone buffer containing 0.1% BSA and 0.05% Tween 20 (pH 8.9).
The plate was blocked with 250 µL of barbitone buffer containing 1% of BSA.
After washing, 50 µL of barbitone buffer, 6 mM EDTA, 0.1% BSA were added
as sample diluent to each well. Fifty µL of standard, control or CSF sample
were then added in duplicate to the plate. The plate was incubated at room
temperature (RT) for 1 h. After washing, 100 µL of the appropriate second
antibody diluted 1:1000 in barbitone buffer were added to each well and the
plate was incubated for 1 h at RT. The microtitre plate was washed and HRP–
labelled swine anti–rabbit antibody diluted 1:1000 was added and incubated
for 1 h at RT. After a final wash, 100 µL of TMB substrate were added. The
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plate was incubated for 20 minutes at RT in the dark, the reaction was stopped
by adding 50 µL 1 M HCl and the absorbance was read at 450 nm with 750
nm as the reference wavelength on a Wallac Victor2.
1.8 Statistical evaluation
All statistical analyses and graphs were done using SAS software (version 8.2,
SAS Institute, Inc., Cary, North Carolina, USA). Independent variables were
compared using the non-parametric two-sample exact Wilcoxon rank-sum test
or the unbalanced two-way ANOVA (general linear model) for more than two
groups [12]. In order to adjust for small sample size significant results were
checked by comparison of proportions with the one–tailed Fisher’s exact test
(α=0.05). The linear relationship between continuous variables was evaluated
using the Spearman correlation coefficient (α=0.05). Linear regression analysis
was performed using the least–squares method.
2 Results
2.1 NfH phosphoforms
2.1.1 Selection of the capture antibody
The standard curves for the NfH capture antibodies binding to phosphory-
lated NfH (NfHSMI34 NfHSMI35 NfHSMI310 NfHNE14 ) and non–phosphorylated
NfH (NfHSMI32 NfHSMI33 NfHSMI37 NfHSMI38 NfHSMI311 ) are shown in Figure
1 A. The signal–to–noise ratio (OD of the lowest standard divided by the OD
of the blank reading) for each standard curve was calculated (Figure 1 B).
The highest signal–to–noise ratio and widest analytical range were obtained
for SMI35 as capture antibody. Therefore SMI35 was chosen as capture anti-
body for further development of the assay.
2.2 Reproducibility of the standard curve
Reproducibility of the standard curve was determined by expressing the op-
tical density (OD) obtained for each calibrant as a percentage of the optical
density. Twenty consecutive standard curves were normalised and the results
averaged. The resulting regression for NfHSMI35 is shown in Figure 2 A and for
NfLNR4 in Figure 2 B.
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2.3 Precision
CSF samples (neat and spiked with either NfH or NfL) were used to calculate
the within- and between–batch precision and recovery.
NfHSMI35 ELISA: the within–batch and between–batch precision was deter-
mined for high and low concentrations of 20 consecutive assays. The within–
batch precision was 5.6% for 2 ng/mL, 6.6% for 0.4 ng/mL, 19.8% for 0.2
ng/mL, averaging to 10.6%. The between–batch precision was 15% for 1.3
ng/mL, 31% for 0.16 ng/mL, averaging to 23%. The detection limit was 0.1
ng/mL. The sensitivity was calculated as the mean + 3 standard deviations of
the blank signal from 20 assays. The sensitivity was 0.2 ng/mL. The recovery
of NfHSMI35 in CSF was 121% for pool 1 and 116% for pool 2, averaging at
119%.
NfLNR4 ELISA: the within–batch precision was 27% for 0.25 ng/mL. The
between–batch precision was over 50%. The sensitivity was 0.25 ng/mL. The
recovery of NfH in CSF was 60% for pool 1 and 66% for pool 2, averaging at
63%.
2.4 Stability and proteolytic susceptibility of NfH and NfL
Stability and susceptibility to proteolysis of NfHSMI35 and NfLNR4 was tested
at room temperature (RT), 4◦C and -70◦C. Five sets of pooled CSF samples
were spiked with NfH or NfL. The CSF pools were then divided into aliquots
of 1 mL and frozen at -70◦C. The aliquots were thawed on day 0, 2, 5 and
7. After thawing the aliquots were stored at 4◦C or RT until analysis. The
measured OD for NfH of the samples was normalised to the OD of day 0
(Figure 3 A). There was a statistical significant difference between the groups
(F(11,51)=2.56, p<0.05). The subgroup analysis revealed that at RT a sig-
nificant decrease of OD was present only between day 0 and day 7 (mean
OD=1 versus 0.76, p<0.01), which could be prevented by adding proteinase
inhibitors. For NfL the SD was to wide to make an accurate statement, some
samples showed an increase and others an exponential decline of CSF NfL
concentrations (data not shown).
In order to measure the succeptibility of NfH and NfL to proteolysis by ALP
aliquots were taken from 2 CSF pools and 10 mU ALP were added. There was
a significant difference between the Nf subunits over the 7 day observation
period (F(7,16)=3.7, p<0.001). The subgroup analysis revealed lower NfH
levels on day 7 compared to day 0 (OD=1 versus OD=0.76, p=0.05). NfL
levels increased from day 1 (OD=1) to day 2 (OD=1.26, p<0.05). However
NfL levels on day 5 (OD=0.12) and day 7 (OD=0.10) were decreased compared
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to day 1 (p<0.001, p<0.001, respectively).
Stability of NfH to repetitive freezing and thawing was tested in 3 pools of
CSF of which 2 aliquots were made. One aliquot was stored at -70◦C, whilst
the other underwent 5 freeze–thaw cycles prior to analysis. The OD of the
latter was normalised to the former. The mean OD of the samples undergoing
5 freeze–thaw cycles was decreased by about 8% (±13%), which remained
within the range of the within–batch precision and did not reach statistical
significance.
2.5 Parallelism
Parallelism between calibrant and CSF was studied by quantifying reciprocal
dilutions of buffer spiked with NfHSMI35 (10 ng/mL, 15 ng/mL and 20 ng/ml)
and CSF samples (11.7 ng/mL, 17.3 ng/mL and 22.4 ng/mL). The obtained
OD for each series of dilutions was normalised to the highest value within
this series (100%). Because of the vertical displacement the top value is not
shown. The parallel relationship is demonstrated in Figure 4. This suggested
the absence of endogenous binding between CSF NfHSMI35 and other CSF
substrates. The NfLNR4 assay was not sensitive enough to allow for accurate
assessment of parallelism between CSF and standards.
2.6 Aggregate formation of purified neurofilaments
The bovine neurofilament heavy chain aggregated in spiked CSF at 4◦C,
-20◦C and -70◦C. Eight pooled samples of spiked CSF were measured without
and after sonication. Samples were sonicated for 1 minute on ice with a cover
of argon gas. Aggregates could be broken up by sonication (Figure 5 A). The
measured amount of NfH for frozen samples after sonication was about twice
as high if compared to samples which were not sonicated. The error-bars (SD)
between the groups overlapped suggesting the presence of aggregates at all
temperatures. Spontaneous disassembly of neurofilament protein aggregates
was tested at RT and 4◦C. In spiked CSF samples spontaneously disassembly
was observed about 3 days after thawing (Figure 5 B). The large errorbars
indicate considerable heterogeneity over this period, probably caused by si-
multaneous presence of aggregate dissolution and proteolysis.
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2.7 Stability of reagents
No problems were found with stability of antibodies. To minimise any problems
with cumulative contamination, the antibodies were stored in 100 µL aliquots
and used within 4 weeks. All buffers were stored at 4◦C and used within 1
week.
2.8 Cross reactivity
Measuring double dilutions of a known amount of protein, the cross–reactivity
of the NfHSMI35 ELISA with bovine NfM was 7.8%, with bovine NfL 6.5% and
with bovine GFAP 0.06%. There was no cross–reactivity with red–cells, white
cells or haemolysed blood.
2.9 Cell–culture and human CNS tissue homogenate
About 25 to 57–fold higher NfHSMI35 levels were found in neuronal (0.68±0.04
ng/mg protein; mean±SD) cell cultures in contrast to microglial (0.027±0.028
ng/mg protein) or astrocytic (0.012±.01 ng/mg protein) cell cultures (Figure
6 A).
The highest NfHSMI35 levels were found in tissue homogenate from human
spinal cord white matter (WM) (213.6±187.5 ng/mg protein), followed by
cortical WM (52.3±32.9) and cortical grey matter (GM, 12.47±11.5 ng/mg
protein, Figure 6 B).
2.10 Reference population
Out of 561 CSF samples 463 were assayed for NfHSMI35 and 127 for NfL. In
29 patients enough CSF was available to assay for NfHSMI35 and NfLNR4 .
CSF NfHSMI35 : the distribution of the NfHSMI35 CSF levels was non–Gaussian
(Figure 7 A). In order to obtain a biological representative population the top
10% (NfH > 1.119 ng/mL) have been removed, leaving 416 patients. The mean
age of the so determined reference population was 42.4±17.9 years, with a
median of 41.9 (IQR 31.2-55.8) years. There was no correlation between CSF
NfHSMI35 and age (R=0.065, p=0.2). Fifty–eight percent (242/416) were fe-
male, 39.9% (166/416) male, and in 8 (1.9%) patients no gender information
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was available. There was no significant difference in CSF NfHSMI35 levels be-
tween the 2 genders.
The relative frequency distribution of the reference–population was then sub-
jected to non–parametric definition of the upper reference value of the 95
percentile [13]. The upper reference value corresponds to 0.73 ng/mL (Figure
7 A, reference line). The mean value of CSF NfHSMI35 was 0.25±0.23 ng/mL
with a median of 0.21 ng/mL and an interquartile range of 0.07 to 0.35 ng/mL.
The data were skewed towards zero by 1.33. The kurtosis was 2.15 indicating
a high slim peak with more values in the tails than expected by the Gaussian
type. This was due to 18% of samples with non detectable CSF NfHSMI35 levels.
CSF NfLNR4 : the distribution of the CSF NfLNR4 levels was non–Gaussian
(Figure 7 B). In order to obtain a biological representative population the top
10% (NfLNR4 > 0.24 ng/mL) have been removed, leaving 113 patients. The 95
percentile corresponds to 0.14 ng/mL (Figure 7 B, reference line). The mean
value of CSF NfLNR4 was 0.024±0.06 ng/mL with a median of 0.00 ng/mL and
an interquartile range of 0.00 to 0.013 ng/mL. The data were skewed towards
zero by 2.9. The kurtosis was 7.4 indicating a high slim peak with more values
in the tails than expected by the Gaussian type. This was due to 71% samples
having no detectable NfLNR4 .
The mean age of the reference population was 46.3±18.2 years, with a median
of 44.7 (IQR 34.7–60.9) years. There was no correlation between CSF NfL
and age (R=0.089, p=0.39). Fifty–two percent (59/113) were female and 42%
(47/113) male, in 7 (6%) patients no gender information was available. There
was no significant difference of CSF NfL levels between the 2 genders.
There was no correlation between CSF NfLNR4 and CSF NfHSMI35 (R=-0.1,
p=0.6) in those 29 samples were both proteins were measured.
2.11 CSF NfHSMI35 in neurological disorders
After determination of the upper reference limit for the NfHSMI35 assay, a
second population of patients was selected according to the clinical diagno-
sis: Nine patients had cluster headache (HD) with no other evidence for or-
ganic pathology in the central nervous system. Two had a space–occupying
lesion (SO) due to one cyst of the right lateral ventricle and one non Hodgkin
lymphoma. Three had amyotrophic lateral sclerosis (ALS), 3 a lumber disc
prolapse (DP), 36 laboratory supported (isolated intrathecal IgG synthesis)
evidence for demyelinating disease (DM), 14 had Guillain–Barre´ syndrome
(GBS) and 5 had a subarachnoid haemorrhage (SAH). All CSF was taken by
routine lumbar puncture, except for SAH where the CSF was taken for routine
infectious screening 2 days after placement of an extra-ventricular drain. The
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values for the SAH therefore represent ventricular CSF.
Because of the small patient numbers statistical significance was checked on
a categorical level by the Fisher’s exact test comparing proportions of pa-
tients with CSF NfHSMI35 levels above the previously calculated upper ref-
erence value (cut–off) of 0.73 ng/mL. A significantly higher number of pa-
tients with SAH had CSF NfHSMI35 levels above cut–off if compared to HD
(p<0.001) or DM (p<0.001). A significantly higher number of patients with
SO had CSF NfHSMI35 levels above cut–off if compared to HD (p<0.05) or
DM (p<0.01) and a significantly higher number of patients with ALS or DP
had CSF NfHSMI35 levels above cut–off if compared to DM (p<0.05, p<0.05,
respectively).
3 Discussion
The novel ELISA method presented here is straight forward and based entirely
on commercially available antibodies. The NfHSMI35 protein was stable over a
1–week period if samples were stored at 4◦C. For longer storage either freezing
at at least -20◦C or addition of a protease inhibitor cocktail is recommended.
The detection limit of the NfHSMI35 ELISA was 0.01 ng/mL and the sensitivity
0.02 ng/mL with a reasonable precision profile (5.6% – 31%). In comparison
the sensitivity of the NfL ELISA was 0.25 ng/mL with a relative poor precision
(CV>50%).
The upper reference value of 0.73 ng/mL NfHSMI35 has to be regarded as con-
servative. It applies to a hospital population of a tertiary referral centre biased
towards neurological diseases. In a general hospital population a more suitable
upper reference value would need to be established, which is likely to be lower.
Because this ELISA is the first one reported to measure NfH in human CSF, no
cross–validation with another NfH assay was possible. An ELISA for measur-
ing NfH in brain homogenate has been reported, but the reproducibility was
not rigorous [2]. An ELISA for quantifying the light chain (NfL) has already
been developed [1]. A stability profile of NfL in CSF was not presented, but
the authors mentioned the high susceptibility of NfL to proteolysis and refer to
previous work [7,8]. This finding is confirmed by the present results. However
the sensitivity of the present NfLNR4 assay only allowed for an approximative
estimate of the kinetics of NfL proteolysis in teh CSF. The strategy chosen
by Rosengren et al. to prevent protease digestion of NfL was to snap–freeze
samples directly after lumbar puncture and store at -70◦C [1]. Samples were
only thawed directly prior to analysis [1].
Repeated freeze–thaw cycles (n=5) did not significantly affect NfHSMI35 stability
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in native CSF. However, for CSF spiked with HPLC purified bovine NfH it
was shown that freezing caused the formation of aggregates. Once aggregates
have formed they could be broken up by sonication. The finding of tempera-
ture and time–dependent increasing NfHSMI35 levels after aggregate formation
suggests the presence of enzymatic breakdown mechanisms. This would also
explain why an initial increase (day 2) of bovine NfL levels was observed after
ALP incubation. After enzymatic release from aggregates NfL would become
accessible to proteolytic enzymes. On the basis that NfL is able to assemble
on its own, whilst NfM and NfH cannot [14] it could be hypothesised that
aggregate formation might be of some relevance for the measurement of NfL.
Rosengren et al. (1996) report a cross–reactivity of their assay with NfH of
15% [1]. The amount of CSF–NfH contributing to the CSF–NfL levels in a
series of studies [1,15,16,17,18] is not known, but could be considerable if the
in–vivo half–life of NfL in the CSF is shorter than that of NfH as suggested
by the present results and others [7,8]. In comparison the cross-reactivity of
the present NfHSMI35 ELISA with NfM (7.8%) or NfL (6.5%) below the ones
reporte by Rosengren et al.. This might be explained by the use of a capture
antibody against an epitope on the C–terminal NfH tail domain which is
unlikely to share homology with NfL or NfM. The possibility of contamination
of the HPLC purified NfL used in this study by some residual NfH should also
be taken into account. This hypothesis should be addressed by the use of
recombinant Nf proteins in future work.
The NfHSMI35 ELISA recognises with high specificity NfH present in primary
neuronal cell cultures, compared to primary astrocytic or microglial cultures.
It is of note that under normal conditions the perikaryal content of phosphory-
lated NfH in neurons is much lower than in axons [3,19]. Therefore it was not
surprising that the highest levels of NfHSMI35 were measured in homogenate
from spinal cord white matter, where axons are packed with high density.
Whilst the ELISA has been optimised for the measurement of NfHSMI35 from
CSF, we found that the range of the assay allows to extend the standard curve
considerable, which was more suitable for measurement of NfHSMI35 from CNS
tissue homogenate.
An important caveat of the present NfHSMI35 ELISA is that the phosphory-
lation and dephosphorylation of NfH is a highly dynamic process [20] likely
to influence the levels of CSF NfHSMI35 . This particularly applies to patho-
logical conditions of the central nervous system [21,22,3,19]. It would be de-
sirable to develop ELISA techniques which would allow to quantify a pro-
file of different NfH phosphoforms. Unfortunately, none of the capture anti-
bodies against non–phosphorylated NfH epitopes in non–phosphorylated NfH
(SMI32, SMI37, SMI38, SMI311) or against a non–phosphorylated epitope
in phosphorylated NfH (SMI33) provided a satisfactory sensitivity with the
present detector system.
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In neurological diseases the highest levels of CSF NfHSMI35 were observed in
the ventricular CSF of patients with SAH, followed by lumbar CSF from
patients with amyotrophic lateral sclerosis, space–occupying lesions and disc
prolapses. The comparison of ventricular with lumbar CSF has to be done
with caution as nothing is known about the NfH concentration across the CSF
compartment. Interestingly, the distribution for CSF NfHSMI35 was bimodal in
GBS patients. This finding warrants further investigation.
In order to accommodate for the emerging need to differentiate between NfH
phosphoforms with immunological methods a new nomenclature has been pro-
posed in Table 1. This nomenclature was based on the name of the capture
antibody and would facilitate the comparison between immunocytochemistry,
immunoblot and ELISA using these antibodies. This nomenclature would also
take into account that the exact binding epitopes are not always known and
that epitope recognition might be influenced by post–translational modifica-
tions. The proposed nomenclature could easily be expanded to incorporate
other capture antibodies which might contribute to distinguish different NfH
phosphoforms.
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Figure 1. (A) NfH phosphoforms. The standard curves for different capture an-
tibodies against phosphorylated (NfHSMI34 = ◦, NfHSMI35 = •, NfHSMI310 = *,
NfHNE14 = ⊕, lines in black) and non–phosphorylated epitopes (NfHSMI32 = 4,
NfHSMI33 = ¦ , NfHSMI37 = ♥, NfHSMI38 = 2, NfHSMI311 = + , lines in grey) are
shown. (B) The signal–to–noise ratio (OD of the lowest standard divided by the
blank OD) for different capture antibodies. A signal–to–noise ratio of greater than
1 (reference line) is mandatory.
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Figure 2. Standard–curve for (A) the NfHSMI35 assay and (B) the NfLNR4 assay.
Reproducibility of twenty consecutive normalised calibration lines. The graph shows
the mean values (dots) ± standard deviation (bars), quadratic regression line, 5%
and 95% confidence interval curves.
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Figure 3. Stability profile of (A) NfHSMI35 in native CSF (n=6) over 7 days at room
temperature (RT) or 4◦C in percentage OD to a sample stored at -70◦C. PI indicates
samples with added protease inhibitors stored at RT. (B) Proteolytic susceptibility
to ALP of NfHSMI35 and NfLNR4 in spiked CSF at room temperature over 7 days.
The mean±SD are shown.
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(closed, black circles). The linear regression, mean (circles) and standard deviation
(horizontal bars) are shown.
20
N
fH
-S
M
I3
5 
[n
g/m
L]
           0
           1
           2
           3
           4
           5
           6
           7
           8
           9
          10
          11
          12
non-sonicated sonicated
RT 4C -20C -70C RT 4C -20C -70C
N
fH
-S
M
I3
5 
[n
g/m
L]
0
1
2
3
4
Day
4C RT
0 1 2 3 4 5 0 1 2 3 4 5
A B
Figure 5. (A) NfHSMI35 aggregate formation in spiked CSF (mean, SD).
Non–sonicated (left) and sonicated (right) samples are shown for 1 week storage
at room temperature (RT), 4◦C, -20◦C and -70◦C. (B) Spontaneous disassembly
of CSF NfHSMI35 aggregates of spiked CSF samples at RT and 4◦C over a 5 day
observation period. The mean±SD are shown.
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Figure 6. Levels of NfHSMI35 ng / mg protein in (A) homogenised neurons, astrocytes
and microglia, (B) in tissue homogenate from cerebral grey matter (GM), white
matter (WM) and spinal cord white matter (mean±SD).
22
N
um
be
r o
f p
at
ie
nt
s
0.0
22.5
45.0
67.5
90.0
NfH-SMI35 [ng/mL]
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 1.1
N
um
be
r o
f p
at
ie
nt
s
0
25
50
75
100
NfL-NR4 [ng/mL]
0.00 0.10 0.20 0.30
A B
Figure 7. Frequency histogram for the reference population for (A) CSF
NfHSMI35 (n=416), the upper reference value of 0.73 ng/mL is shown (dotted line).
(B) CSF NfLNR4 (n=113), the upper reference value of 0.14 ng/mL is shown (dotted
line).
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Figure 8. Scatter plot of CSF NfHSMI35 levels in patients with cluster headache
(HD), space–occupying lesions (SO), amyotrophic lateral sclerosis (ALS), disc pro-
lapse (DP, demyelinating disease (DM), Guillain–Barre´ syndrome (GBS) and sub-
arachnoid haemorrhage (SAH). The horizontal reference line (dotted) represents the
cut–off (0.73 ng/mL) derived from the reference population, the y–axis is split at 2
ng/mL.
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